JAK2 and cancer: Previously, we found that chemotherapy topoisomerase inhibitors could promote the ROS-elevated expression and secretion of CXCL1, activating JAK2-STAT1 signaling pathway and inactivating PTP1B, thereby promoting the migration and invasion of cancer cells22.